<DOC>
	<DOCNO>NCT00903175</DOCNO>
	<brief_summary>This study assess efficacy safety first-line RAD001 follow second-line sunitinib versus opposite sequence : first-line sunitinib follow second-line RAD001 treatment patient MRCC .</brief_summary>
	<brief_title>Efficacy Safety Comparison RAD001 Versus Sunitinib First-line Second-line Treatment Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients advance renal cell carcinoma . 2 . Patients least one measurable lesion . 3 . Patients Karnofsky Performance Status ≥70 % . 4 . Adequate bone marrow function . 5 . Adequate liver function . 6 . Adequate renal function . 7 . Left ventricular ejection fraction ( LVEF ) ≥ low limit institutional normal ( LLN ) 8 . Women childbearing potential must negative serum pregnancy test within 14 day prior administration study medication . Adequate contraception must use study . 1 . Less 4 week postmajor surgery 2 . Patients radiation therapy within 4 week prior start study treatment ( palliative radiotherapy bone lesion allow within 2 week prior study treatment start ) . 3 . Patients need major surgical procedure course study 4 . Patients serious nonhealing wound , ulcer , bone fracture 5 . Patients history seizure ( ) control standard medical therapy 6 . Patients receive prior systemic treatment metastatic RCC 7 . Patients previously receive systemic mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) VEGF inhibitor . Note : History adjuvant immunotherapy , vaccine adjuvant sorafenib follow localized surgical nephrectomy acceptable . 8 . Patients know hypersensitivity RAD001 ( everolimus ) rapamycins ( sirolimus , temsirolimus ) excipients Patients know hypersensitivity RAD001 ( everolimus ) rapamycins excipients 9 . Patients know hypersensitivity sunitinib excipients 10 . History clinical evidence central nervous system ( CNS ) metastases . Note : Subjects previouslytreated CNS metastasis ( surgery plus minus radiotherapy , radiosurgery , gamma knife ) meet 3 follow criterion eligible : Are asymptomatic , evidence active CNS metastases ≥ 6 month prior enrollment , requirement steroid enzymeinducing anticonvulsant ( EIAC ) 11 . Clinically significant gastrointestinal abnormality include , limited : Malabsorption syndrome Major resection stomach small bowel could affect absorption study drug Active peptic ulcer disease Inflammatory bowel disease Ulcerative colitis , gastrointestinal condition increase risk perforation History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 28 day prior begin study treatment . 12 . Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥160mmHg diastolic blood pressure ( DBP ) ≥ 95mmHg ] 13 . Patients receive chronic systemic treatment corticosteroid another immunosuppressive agent 14 . Patients known history HIV seropositivity . 15 . Patients active bleeding . 16 . Patients severe and/or uncontrolled medical condition condition within past 12 month could affect participation study : Cardiac angioplasty stenting , unstable angina pectoris , symptomatic peripheral vascular disease , symptomatic congestive heart failure ( NYHA II , III , IV ) , myocardial infarction ≤ 6 month prior first study treatment , serious uncontrolled cardiac arrhythmia , cerebrovascular accident ≤ 6 month study treatment start . Prolongation correct QT interval ( QTc ) &gt; 500 millisecond ( msec ) . Severally impaired lung function define spirometry DLCO 50 % normal predict value and/or 0^2 saturation 88 % less rest room air . Poorly control diabetes define fast serum glucose &gt; 2.0 x ULN . Any active ( acute chronic ) uncontrolled infection/disorders impair ability evaluate patient patient complete study . Liver disease chronic active hepatitis chronic persistent hepatitis . 17 . History cerebrovascular accident ( CVA ) include transient ischemic attack ( TIA ) . 18 . History pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible . 19 . Patients history another primary malignancy treatment ≤ 3 year 20 . Female patient childbearing potential use adequate birth control method , pregnant breast feeding . 21 . Patients use investigational agent receive investigational drug ≤ 2 week prior study treatment start . 22 . Patients unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>RAD001</keyword>
	<keyword>everolimus</keyword>
	<keyword>sunitinib</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>metastatic renal cell cancer</keyword>
	<keyword>advanced kidney cancer</keyword>
</DOC>